360° Coverage : Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at...

1 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is...

Filed under: news

YouTube Videos

 
 
 

1 year ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

Indian American scientist develops path to brighter LCD displays
Washington, Nov 24 (IANS) Researchers led by an Indian-American have developed a polarising filter that can result in mobile device displays that last much longer on a single battery charge and cameras that can shoot in dim light.
 
 
Xi Jinping-Peng Liyuan love story goes viral on internet
Beijing, Nov 24 (IANS/EFE) A music video that tells the story of the deep love between Chinese President Xi Jinping and his wife Peng Liyuan has gone viral on the internet with more than 22 million views in a week, the People's Daily reported Monday.
 
 
Italian doctor contracts Ebola in Sierra Leone
Rome, Nov 24 (IANS) A doctor working for a voluntary organisation in Sierra Leone has become the first Italian to contract Ebola, media reported Monday.
 
 
Complete fossil of small dinosaur found
Seoul, Nov 24 (IANS/EFE) South Korean paleontologists have found a complete fossil of a small dinosaur in rare condition, the first such discovery of its kind in the country, according to the National Research Institute of Cultural Heritage in Seoul.
 
 
 

Latest from the Network

Turkey rejects easing relations with Egypt
Istanbul, Nov 24 (IANS) Turkish President Recep Tayyip Erdogan said Monday that he rejected the reconciliation efforts for friendly relations with Egypt. Turkey does not accept the legitimacy of Egyptian President...
Read more on Politics Balla
 
US defence chief Chuck Hagel forced out
Washington, Nov 24 (IANS) In a surprise development, US Defense Secretary Chuck Hagel resigned Monday reportedly under pressure amid criticism of President Barack Obama's national security team over how to deal with...
Read more on Politics Balla
 
Bette Midler slams 'silly' Ariana Grande
Bette Midler has slammed Ariana Grande's ''silly high voice''. The 68-year-old actress hit out at the 21-year-old star's sexy music videos for being ''silly beyond belief'', and insists the 'Bang Bang' hitmaker's...
Read more on Celebrity Balla
 
Demi Lovato: Me and Miley have nothing in common
Demi Lovato insists she and Miley Cyrus won't be friends again because they have nothing in common. The 22-year-old singers were good pals during their rise to fame but the 'Heart Attack' hitmaker admits that while she...
Read more on Celebrity Balla
 
Indian American scientist develops path to brighter LCD displays
Washington, Nov 24 (IANS) Researchers led by an Indian-American have developed a polarising filter that can result in mobile device displays that last much longer on a single battery charge and cameras that can shoot...
Read more on Politics Balla
 
Kohl's Black Friday Sale launched Online
The Kohl's Black Friday 2014 sale starts at 6pm on Thanksgiving Day in stores, but has launched now on kohls.com. Kohl's offers again the popular $15 Kohl's Cash on every $50 spent in this year's Black Friday sale. This...
Read more on Black Friday Countdown
 
Brenton Thwaites for Pirates of the Caribbean: Dead Men Tell No Tales
Brenton Thwaites will star in 'Pirates of the Caribbean: Dead Men Tell No Tales'. The star will play the role of British soldier Henry, beating fellow actors such as Ansel Elgort of 'The Fault In Our Stars' and George...
Read more on Movie Balla
 
Josh Hutcherson 'moves on' from young adult movies
Josh Hutcherson wants to ''move on'' from young adult films like 'The Hunger Games'. The 22-year-old actor - who has starred in four films based on the dystopian 'Hunger Games' novels since 2011 - plans to explore other...
Read more on Movie Balla
 
33 IS militants killed in Iraq's Mosul, two towns retaken (Roundup)
Baghadad, Nov 24 (IANS) At least 33 militants of the Islamic State (IS) died Monday in the Iraqi city of Mosul and the surrounding area, including a leader who was responsible for the sale of kidnapped Yazidi women,...
Read more on Politics Balla
 
Jailbreak in Argentina, 32 inmates escape
Buenos Aires, Nov 24 (IANS/EFE) Thirty-two inmates escaped over the weekend from a police jail in Rosario, a city in central Argentina, police said Monday. The inmates broke out of the jail Sunday by threatening the...
Read more on Politics Balla